Schrodinger Inc (SDGR) Q4 2025 Earnings Call Transcript

Why It Matters

The results prove Schrödinger’s hybrid SaaS‑plus‑collaboration model can scale revenue while preserving cash, positioning the firm to monetize its expanding drug‑discovery pipeline and predictive‑toxicology tools.

Key Takeaways

• Revenue $54.8M, 16% YoY increase.
• Software margin fell to 68% due to mix shift.
• Net loss narrowed to $43M, 59¢ per share.
• Phase I SGR1505 shows activity in refractory lymphomas.
• $30M expense cut lowers operating costs.

Pulse Analysis

Schrödinger’s second‑quarter performance underscores the resilience of its computational chemistry platform amid a challenging biotech financing environment. Revenue growth was powered by both hosted software contracts and a sizable Novartis collaboration upfront payment, while the company leveraged a $30 million cost‑reduction initiative to trim R&D and operating expenses. Although gross margins fell as the revenue mix tilted toward lower‑margin services and the predictive toxicology effort, the firm’s cash runway remains robust, giving it flexibility to invest in high‑impact R&D and strategic partnerships.

The launch of a beta predictive toxicology module reflects Schrödinger’s push to embed AI‑driven safety assessments into early‑stage drug design, aligning with FDA’s push for alternative methods. This initiative, funded in part by a Gates Foundation grant, expands the platform’s off‑target prediction suite to include HERG, PXR and key cytochrome P450 enzymes, enhancing its value proposition for pharmaceutical and biotech customers seeking to reduce animal testing and accelerate lead optimization. The shift toward cloud‑based contracts further drives recurring revenue, even as on‑premise renewals lag.

Clinically, the company’s proprietary pipeline gained momentum with Phase I data for SGR1505, a MALT1 inhibitor showing tolerability and monotherapy signals in heavily pre‑treated CLL and Waldenström’s macroglobulinemia patients. The fast‑track designation and early efficacy signals have prompted management to explore partnership models for later‑stage development, potentially unlocking milestone payments and royalty streams. Coupled with upcoming data from SGR2921 and SGR3515, Schrödinger is positioned to translate its computational platform into tangible therapeutic value, supporting its guidance for continued software revenue growth and a drug‑discovery revenue target of $45‑$50 million for FY2025.